|
FDA staff question Roche drug breast cancer data |
|
Friday, 16 July 2010 00:00 |
|
(Reuters) - The benefits of Roche AG's Avastin may not outweigh the risks for patients with advanced breast cancer, U.S. reviewers said on Friday, knocking the Swiss company's stock down 4 percent on fears that regulators could restrict marketing of the blockbuster drug.
|